Dr. Stephen Scally

The Walter and Eliza Hall Institute of Medical Research

biography

Stephen Scally is a Team Leader at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, where he leads a research program focused on understanding the structural basis of malaria parasite invasion and immunity. His work integrates structural biology, immunology and parasitology to identify protective immune responses and develop next-generation malaria vaccines, with a particular focus on multi-stage vaccine targets.

Title

Targeting PTRAMP-CSS potently inhibits P. falciparum across blood, liver and mosquito stages

abstract

Malaria, caused by Plasmodium falciparum spans liver, blood, and mosquito stages, limiting the effectiveness of single-stage vaccines. The PTRAMP-CSS heterodimer, a core component of the essential PCRCR invasion complex, is expressed on merozoites, mature gametocytes, and salivary gland sporozoites, enabling single-antigen targeting across multiple lifecycle stages. Nanobodies against PTRAMP-CSS block merozoite invasion of erythrocytes, reduce mosquito infection in membrane-feeding assays, and inhibit sporozoite invasion of primary human hepatocytes. High-resolution crystal structures of inhibitory and non-inhibitory nanobody-antigen complexes identify conserved inhibitory epitopes and guide the design of bispecific nanobody Fc constructs with enhanced potency. In semi-immune Kenyan CHMI samples, higher baseline IgG to PTRAMP-CSS and Ripr is associated with improved parasite control. By demonstrating conserved vulnerability across all three major lifecycle stages, PTRAMP-CSS offers a realistic path to single-antigen, multistage vaccines and biologics that aim to prevent disease and block transmission.